Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00092053 | Study of Investigational Drug in Osteoporosis (MK-0217-908) | PHASE3 | COMPLETED | 203 | — | — | Dec 1, 2004 | Jul 1, 2005 | Feb 2, 2022 | - | — |
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Participants will receive 3 placebo tablets once a month, for 3 months, on the first day of each treatment cycle. |
| ibandronate 100 mg | EXPERIMENTAL | Participants will receive 2 ibandronate 50 mg tablets and 1 placebo tablet once a month, for 3 months, on the first day of each treatment cycle. |
| ibandronate 150 mg | EXPERIMENTAL | Participants will receive 3 ibandronate 50 mg tablets once a month, for 3 months, on the first day of each treatment cycle. |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | tablets |
| ibandronate | DRUG | 50 mg tablets |
Inclusion Criteria: -postmenopausal for at least 3 years, with osteoporosis at any of the following sites: \[BMD \> 2.0 standard deviations below young normal mean bone mass for the hip trochanter, PA lumbar spine (L1 to L4), total hip, or femoral neck based on the normative database provided by eac...